OmniAb, Inc. (NASDAQ:OABI) Position Cut by Chicago Capital LLC

Chicago Capital LLC trimmed its stake in OmniAb, Inc. (NASDAQ:OABI) by 5.9% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 2,975,451 shares of the company’s stock after selling 187,104 shares during the quarter. Chicago Capital LLC’s holdings in OmniAb were worth $10,533,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Barclays PLC raised its stake in shares of OmniAb by 321.5% during the third quarter. Barclays PLC now owns 143,215 shares of the company’s stock valued at $606,000 after purchasing an additional 109,236 shares in the last quarter. FMR LLC grew its holdings in OmniAb by 10.6% during the third quarter. FMR LLC now owns 138,813 shares of the company’s stock worth $587,000 after acquiring an additional 13,324 shares during the period. Atria Investments Inc acquired a new position in OmniAb during the third quarter worth about $148,000. Murchinson Ltd. acquired a new position in OmniAb during the third quarter worth about $4,230,000. Finally, State Street Corp grew its holdings in OmniAb by 1.7% during the third quarter. State Street Corp now owns 2,031,676 shares of the company’s stock worth $8,594,000 after acquiring an additional 34,654 shares during the period. 72.08% of the stock is currently owned by institutional investors.

OmniAb Stock Up 0.3 %

Shares of NASDAQ OABI opened at $3.22 on Monday. The business’s 50 day moving average is $3.58 and its two-hundred day moving average is $4.00. The company has a market cap of $454.73 million, a P/E ratio of -5.19 and a beta of -0.10. OmniAb, Inc. has a 12 month low of $3.10 and a 12 month high of $6.55.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $11.00 target price on shares of OmniAb in a report on Thursday, November 14th. Benchmark reissued a “buy” rating and issued a $8.00 price target on shares of OmniAb in a research note on Thursday, November 14th.

Insiders Place Their Bets

In other OmniAb news, CEO Matthew W. Foehr sold 41,811 shares of the company’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $3.24, for a total value of $135,467.64. Following the sale, the chief executive officer now directly owns 3,749,639 shares in the company, valued at $12,148,830.36. This represents a 1.10 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Kurt A. Gustafson sold 15,526 shares of the company’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $3.24, for a total value of $50,304.24. Following the completion of the sale, the chief financial officer now owns 212,720 shares in the company, valued at $689,212.80. This trade represents a 6.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 82,826 shares of company stock valued at $268,356 in the last three months. Company insiders own 8.60% of the company’s stock.

OmniAb Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.